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of the biologic agents currently utilized in the United States for
this indication (adalimumab, alefacept, efalizumab, etanercept
and inﬂiximab). Model results were displayed for a time horizon
of one year based on a switch to an appropriate alternate biologic
agent in the event of suboptimal clinical response. Multiple one-
way sensitivity analyses were conducted. RESULTS: Across all
the biologics evaluated there are signiﬁcant differences in PASI 75
response at 12 weeks versus longer term (ranging from 59% to
20% across the agents at the end of one quarter of treatment and
at the end of four quarters of treatment, respectively). The cost
per PASI 75 was observed to be $26,460, $31,191, $28,217,
$30,544 and $30,983 for therapy initiated with adalimumab,
alefacept, efalizumab, etanercept and inﬂiximab, respectively.
CONCLUSION: While there are signiﬁcant differences in the
cost of the studied biologic agents initially, the CE results tend to
converge over the ﬁrst year of treatment. Further research needs
to be conducted to evaluate the CE of treatment beyond a one-
year period.
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OBJECTIVE: In western countries AMD is considered one of the
most important causes of blindness among persons over 65 years
old. The purpose of this study was to determine the cost-
effectiveness of pegaptanib vs verteporﬁn in the treatment of
AMD from the health care payer’s perspective. METHODS: A
seven-stage stochastic Markov model based on visual acuity (VA)
in the better seeing-eye (stages: with clinical beneﬁt, VA>20/40;
VA:20/40–20/; VA:20/100–20/160; VA:20/200–20/500; VA < 20/
500 and legal blindness) was performed during a ﬁve-year
period. Effectiveness measure used in the assessment was the
probability to gain at least one-level of VA at the end of the
follow up period. Effectiveness data was obtained from interna-
tional published literature. Comparators used in the model were
pegaptanib 0.3 mg (8 sessions) and verteporﬁn 15 mg (10 ses-
sions). Resource use and cost data were obtained from hospital
records and ofﬁcial institutional databases from the Social Secu-
rity Mexican Institute (IMSS). Costs and health outcomes were
discounted with a 3% annual rate. The model was calibrated.
Probabilistic sensitivity analyses were performed to determine
the results robustness. RESULTS: Patients who received pegap-
tanib experienced a higher probability to gain at least one level of
VA(57.4%; CI95%:52.26%–62.54%) compared with patients
treated with verteporﬁn (13.8%; IC95%:10.61%–16.99%) con-
sidering an initial VA state of “>20/40”(p < 0.001). Mean total
costs per patient were higher in patients who received pegaptanib
compared to those who received verteporﬁn (US$6749;
CI95%:US$6401–US$7096 vs. US$6311 CI95%:US$5948–
US$6674; respectively). The ICER in patients receiving pegap-
tanib compared to those receiving verteporﬁn was US$1004
(CI95% US$926–US$1090). Sensitivity analyses found that
pegaptanib is a cost-saving strategy when the numbers of sessions
given to the patients are less than three. CONCLUSION: The
results show that in Mexico, pegaptanib is a cost-effective
therapy for AMD when is compared with verteporﬁn. These
results should be taken into account by Mexican decision makers
in the management of patients with AMD.
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OBJECTIVE: Blepharokeratoconjunctivitis (BKC) is a disease
characterized by inﬂammation of the eye lid, conjunctiva and
cornea and is typically treated empirically with topical antibiotic/
anti-inﬂammatory agents. The purpose of this study was to
compare the cost-effectiveness of tobramycin 0.3%/loteprednol
0.5%, (Zylet) to tobramycin 0.3%/dexamethasone 0.1%, (Tobra-
dex) for the rapid control of BKC. METHODS: Effectiveness
data for this analysis came from a randomized, double-masked,
parallel-group study of forty patients with BKC. Patients were
treatedwith eitherZylet™orTobradex®administered twice daily
in the test eye. Themeasure of effectiveness usedwas the change in
a clinical composite score of four BKC components: blepharitis,
ocular discharge, conjunctivitis, and corneal punctuate epithelial
keratopathy (PEK). Each clinical component was graded on a
scale of 0 (minimum) to three (extensive) and assessed at baseline
and on day 4 (1) of therapy. Five different pharmacy chains were
surveyed as to their prices for a 5ml bottle of both Tobradex and
Zylet. The average price of each agent was used as the cost
measure in the analysis. A probabilistic sensitivity analysis evalu-
ated the robustness of the economic outcomes. The economic
perspective was that of the payer. Due to the short time span
no cost discounting was performed. RESULTS: Reductions in
the BKC clinical composite scores at the day-4 assessment were
calculated at 4.5 (SD  1.7) versus 7.1 (SD  1.2) for the Zylet
and Tobradex groups, respectively. The average retail costs for
Zylet and Tobradex were $96.45 (SD  $5.26) and $71.75
(SD  $5.48) respectively. The cost-effectiveness ratios for Zylet
and Tobradex therapy were $21.43 and $10.10, respectively. The
cost-effectiveness results remained consistent using the probabi-
listic sensitivity distributions tested. CONCLUSION: Tobradex
economically dominated Zylet for the rapid control of BKC
because it was both less costly and more effective.
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OBJECTIVE: InGermany, 26%of reported and 36% (= 8’460) of
conﬁrmed work-related diseases are skin-related, in over 90% of
these cases hands are affected. However, there is a lack on com-
prehensive information on costs associated with chronic hand
eczema (CHE). The objective of this study was to assess the direct
and indirect costs of CHE.METHODS:Data on 151 Patientswith
occupational skin diseases entering a special rehabilitation
program were assessed for the preceding 12 months. Data were
derived from patient records and direct patient information.
Descriptive analyses froma societal perspectivewas performed for
all patients and by physician-rated severity (severity group 1:
no/mild; group 2: moderate/severe). DGUV (German Statutory
Accident Insurance) was the payer for all patients. RESULTS:
Mean age was 44.9 years, 64.9% of patients were male. Total
mean annual costs amounted to €8.160 (95% CI: 6.395–9.925)
per patient. Indirect costs represented 75% of total costs,
in-patient-rehabilitation 14%. Each other factor (out-patient ser-
vices, diagnostics, drugs, complementary therapies, out-of-pocket
expenses) contributed < 3% to overall costs. Disease severity
inﬂuencedQoL signiﬁcantly (DLQI-score of severity group 1: 7.9,
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95% CI 6.5–9.3; group 2: 12.9, CI 11.3–14.4) but not direct
treatment costs (€2.033 vs. €1.991 respectively). There was a
trend for higher indirect costs in patients in severity group 2
(€5.120, CI €2.717–€7.523 vs. €6.796, CI €3997–€9596). CON-
CLUSION: Total annual costs of new cases covered by DGUV
with conﬁrmed occupational etiology is estimated to amount to
€55million, considering also patientswith suspected occupational
etiology increases costs to €96 million. Total costs of prevalent
cases can be expected to amount tomultiples of this ﬁgure. Disease
severity, although impacting patient’s QoL, has little inﬂuence on
treatment patterns and costs. Indirect costs, by far the most
important cost factor, tend to increase with severity.
PSS22
THE ANNUAL COST OF BACTERIAL CONJUNCTIVITIS INTHE
UNITED STATES: EVIDENCE FROM AN ECONOMIC
MODELLING APPROACH
Smith AF1,Waycaster C2
1Medmetrics Inc, Ottawa, ON, Canada, 2Alcon Laboratories Inc, Fort
Worth,TX, USA
OBJECTIVE: The aim of this study was to determine the annual
direct costs of treating bacterial conjunctivitis (BC) in the United
States. METHODS: A systematic review of the medical literature
was supplementedwith information fromdetailed physician inter-
views on resource utilization associated with bacterial conjunc-
tivitis therapy in theUnited States. Data on the annual incidence of
BC was obtained from an analysis of the National Ambulatory
Medical Care Survey (NAMCS) database for the year 2005.
Cost estimates for resource utilization such as physician visits and
prescription drugs were taken from standard cost reference
sources. Due to the acute nature of BC no cost discounting was
performed. The economic perspective presented is that of the
payer. All costs are expressed in 2007 USD. RESULTS: The
number of BC cases in the United States for 2005 was estimated at
4,016,544, yielding an estimated annual incidence rate of 135.46
per 10,000. Base-case analysis estimated the direct cost of treating
patients with bacterial conjunctivitis in the United States at
US$765,063,696. One-way sensitivity analysis assuming either a
20% variation in the annual incidence of bacterial conjunctivitis
or treatment costs generated a cost range of US$612,050,957 to
US$918,076,435. Two-way sensitivity analysis assuming a 20%
variation in both the annual incidence of bacterial conjunctivitis
and treatment costs occurring simultaneously resulted in an
estimate cost range of US$489,627,912 to US$1,101,711,002.
CONCLUSION: This study reports the ﬁrst known estimate of
the direct costs of treating and managing patients with bacterial
conjunctivitis in the United States. The economic burden of this
condition is substantial. Our estimates represent conservative
amounts because indirect costs were not considered in the analy-
sis. This information may prove useful to decision makers with
respect to the adequate allocation of health care resources neces-
sary to address the economic burden of BC in the United States.
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OBJECTIVE: To describe treatment outcomes and to evaluate
resource utilization and associated cost of proactive use of
tacrolimus ointment (PU) versus standard use of tacrolimus oint-
ment (SU) in children with moderate or severe atopic dermatitis
(AD) over a period of 12 months. METHODS: A pan-European,
phase III multicentre randomized clinical trial FG-506-06-41
‘CONTROL’ was conducted. After randomization patients (2–15
years old) applied tacrolimus 0.03% ointment (PU) or vehicle
ointment (SU) at the usually affected areas twice per week for
12 months. Disease exacerbations were treated using open-label
tacrolimus 0.03% ointment twice daily. Resource utilization data
(e.g. for ointments, drugs, doctor consultations, out-of-pocket-
expenses, absence from school) were collected alongside the
clinical trial by caregiver questionnaires, prospectively. Costs
of pooled resource data were determined using German unit cost
data. Direct and indirect costs were considered from third party
payer (TPP), caregiver, and societal perspectives. RESULTS: 146
patients were included in the analysis, 75 PU patients (53%
moderately affected) and 71 SU patients (51% moderately
affected). Mean age of patients was 7 years (SD 3.9/4.5) in both
treatment groups. Mean + SD body surface area in both groups
was 1.0 + 0.4 m2. The mean number of disease exacerbations
requiring substantial therapeutic intervention in the PU and SU
arms was 1.7 + 2.2 and 3.4 + 3.2 (p < 0.001), respectively. In
patients with severe AD the mean total annual cost per patient
was higher in the standard regimen €2,002 + 2,315 compared to
PU €1,571 + 1,122. In the subgroup of severely affected 2–6
year-old patients these cost differences were larger in favour of
tacrolimus ointment: €1,465 + 837 (PU) versus €2,253 + 2,855
(SU). In moderately affected patients there were no cost differ-
ences: €1,233 + 1,507 (PU) and €1,136 + 1,494 (SU). CONCLU-
SION: Proactive treatment with tacrolimus 0.03% ointment is
more effective and leads to cost savings in comparison to stan-
dard treatment with tacrolimus 0.03% ointment, especially in
children with severe AD.
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OBJECTIVE: Acne is a common dermatological condition and
impacts millions of adolescent and adult lives in the United States
(US). The purpose of this study was to accurately quantify the
cost per episode for the treatment of acne in the US and to
examine disparities in treatment costs. METHODS: Information
was collected from the PharMetrics Integrated Patient-centric
Database, a large collection of administrative claims in the year
2004. The database included more than 80 public and private
health care plans included in the database, representing approxi-
mately 9.6 million unique patients. Analysis was performed using
the Total Resource Utilization (TRU) Benchmarks process, a
descriptive methodology which organizes and separates informa-
tion from the third-party database, into accessible benchmarks
for comparison. RESULTS: There are many different drug treat-
ment therapies that can be used to treat acne which can range in
price dramatically. The average acne episode cost $777.19, with
pharmacy costs representing 59.5% and outpatient costs repre-
senting 39.1%. Inpatient services were reported in only 0.1% of
acne episodes and were associated with $9,297.56 in costs. For
patients diagnosed with acne, pharmacy visits represented 85.5%
of all episodes. Average outpatient costs were $303.99, attribut-
able to 3.73 outpatient services with 2.18 of these services were
physician visits. The lowest average total episode costs were
found in the South-central region and were $624.05. The highest
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